Article in Breast (Edinburgh, Scotland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 4 institutions in 1 country.
Kimberly A BertrandSlone Epidemiology Center at Boston University, Boscton, MA, USA. Electronic address: kab15@bu.edu.
Traci N BetheaSlone Epidemiology Center at Boston University, Boscton, MA, USA.
Lynn RosenbergSlone Epidemiology Center at Boston University, Boscton, MA, USA.
Elisa V BanderaRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Thaer KhouryRoswell Park Cancer Institute, Buffalo, NY, USA.
Melissa A TroesterGillings School of Global Public Health, University of North Carolina at Chapel Hill, NC, USA.
Christine B AmbrosoneRoswell Park Cancer Institute, Buffalo, NY, USA.
Julie R PalmerSlone Epidemiology Center at Boston University, Boscton, MA, USA.
Boston University · USRoswell Park Comprehensive Cancer Center · USRutgers, The State University of New Jersey · USUniversity of North Carolina at Chapel Hill · US
Funding
Tissue Procurement & PathologyP50CA058223 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KATHERINE A. HOADLEY · 1992 to 2026
$59.3M
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa A. Troester · 2001 to 2026
$36.3M
A Follow-up Study for Causes of Cancer in Black WomenU01CA164974 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Kimberly A. Bertrand, Yvette C Cozier · 2017 to 2026
$24.0M
FOLLOW-UP STUDY FOR CAUSES OF ILLNESS IN BLACK WOMENR01CA058420 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ROSENBERG, LYNN · 1999 to 2013
$20.7M
Reproduction, Lactation and Hormonal Factors in Breast Cancer SubtypesP01CA151135 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI AMBROSONE, CHRISTINE B., OLSHAN, ANDREW · 2011 to 2017
$18.1M
A Follow-up Study for Causes of Cancer in Black WomenUM1CA164974 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ROSENBERG, LYNN · 2012 to 2017
$13.7M
Gene Polymorphisms in Relation to Cancer in Black WomenR01CA098663 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI PALMER, JULIE R · 2003 to 2012
$5.3M
Race &Risk Factors for Early/Aggressive Breast CancerR01CA100598 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI AMBROSONE, CHRISTINE B. · 2004 to 2008
$4.8M
An assessment of whether aspirin and/or vitamin D improves breast cancer outcomes in Black women and the modifying effect of genetic variantsK01CA212056 · NCI · GEORGETOWN UNIVERSITY · PI BETHEA, TRACI N. · 2017 to 2021
backgroundCompared to U.S. white women, African American women are more likely to die from ductal carcinoma in situ (DCIS). Elucidation of risk factors for DCIS in African American women may provide opportunities for risk reduction.
methodsWe used data from three epidemiologic studies in the African American Breast Cancer Epidemiology and Risk Consortium to study risk factors for estrogen receptor (ER) positive DCIS (488 cases; 13,830 controls). Results were compared to associations observed for ER+ invasive breast cancer (n = 2,099).
resultsFirst degree family history of breast cancer was associated with increased risk of ER+ DCIS [odds ratio (OR): 1.69, 95% confidence interval (CI): 1.31, 2.17]. Oral contraceptive use within the past 10 years (vs. never) was also associated with increased risk (OR: 1.43, 95%CI: 1.03, 1.97), as was late age at first birth (≥25 years vs. <20 years) (OR: 1.26, 95%CI: 0.96, 1.67). Risk was reduced in women with older age at menarche (≥15 years vs. <11 years) (OR: 0.62, 95%CI: 0.42, 0.93) and higher body mass index (BMI) in early adulthood (≥25 vs. <20 kg/m
conclusionsOur findings suggest that most risk factors for invasive ER+ breast cancer are also associated with increased risk of ER+ DCIS among African American women.
Indexed as
AdolescentAdultAgedBlack or African AmericanBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingFemaleHumansMiddle AgedReceptors, EstrogenRisk FactorsUnited StatesYoung AdultReceptors, EstrogenAfrican AmericanBreast cancerDuctal carcinoma in situEpidemiologyRisk factors
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Risk factors for estrogen receptor positive ductal carcinoma in situ of the breast in African American women. · full record | OpenQuestion